<DOC>
	<DOCNO>NCT01900574</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( body study medication ) safety subcutaneously ( skin ) administer golimumab pediatric participant ( age 2 17 year ) moderately severely active Ulcerative Colitis ( UC ) .</brief_summary>
	<brief_title>A Study Assess Safety Pharmacokinetics Subcutaneously Administered Golimumab , Human Anti-TNFα Antibody , Pediatric Patients With Moderate Severe Active Ulcerative Colitis</brief_title>
	<detailed_description>This open-label ( [ participant investigator ] know treatment participant receive ) multicenter study . The study divide 2 part : Part 1 : pharmacokinetics portion ( Week 0 Week 14 ) ; Part 2 : study extension ( Week 14 Week 114 ) . The focus study evaluate pharmacokinetics safety golimumab . Additionally efficacy short-term therapy golimumab evaluate . Participants clinical response Week 6 continue receive open label golimumab maintenance therapy enter study extension Week 14 . Participants clinical response Week 6 withdrawn treatment golimumab . At Week 114 , participant , opinion investigator , may benefit continued treatment eligible continue receive golimumab every 4 week market authorization obtain treatment pediatric UC country , decision make pursue indication pediatric UC . Approximately 30 participant enrol study . The total duration study participation participant approximately 126 week longer .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Moderate severe Ulcerative Colitis ( UC ) define Mayo score ( score use assess treatment UC ) 6 12 inclusive , include endoscopic subscore 2 . Must either currently receive treatment , history fail respond , medical contraindication least 1 follow therapy : oral intravenous corticosteroid , 6mercaptopurine azathioprine OR must either history corticosteroid dependency ( ie , inability successfully taper corticosteroid without return symptom UC ) OR require 3 course corticosteroid past year No history latent active tuberculosis prior screen Positive protective antibody titer varicella measles prior first administration study agent Exclusion criterion : Have severe extensive UC likely require colectomy ( surgical removal colon ) within 12 week study entry Have UC limit rectum le 20 cm colon Presence stoma Presence history fistula Have evidence Crohn 's disease ( inflammatory large intestine disease ) Previous exposure antitumor necrosis factor therapy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Colitis , Ulcerative</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Moderately Severely Active Ulcerative Colitis</keyword>
	<keyword>Golimumab</keyword>
	<keyword>Simponi</keyword>
	<keyword>Human anti-TNFα Antibody</keyword>
	<keyword>Pediatric participant</keyword>
	<keyword>Safety Pharmacokinetics</keyword>
</DOC>